AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02173509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary and multifaceted educational intervention.
Description: Outreach visits (40 minutes) which included a PowerPoint presentation and impress materials: poster; flyers; participation certificate and articles mentioned in the presentation. This outreach visit aimed to change the knowledge-attitudes previously identified in a previous study as being associated with poor prescribing of antibiotics in the case of physicians and propensity to dispense antibiotics without medical prescription in the case of pharmacists.
Study NCT01490905 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Theramine (A medical food)
Description: Theramine two capsules twice daily for 28 days.
Study NCT01490905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theraprofen
Description: Theramine two capsules twice daily and ibuprofen 400mg once daily for 28 days.
Study NCT01490905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 400mg once daily for 28 days.
Study NCT01707576 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: consultation 10 days later
Description: new depression screening
Study NCT02560077 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subject receive the Placebo product (placebo group had same color and smell of treatment groups)
Study NCT02560077 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cashew apple juice
Description: Subject received the cashew apple juice at dose of 120 mg/day after meal
Study NCT02560077 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cashew apple juice
Description: Subject received the cashew apple juice at dose of 240 mg/day after meal
Study NCT00621348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic fluid
Description: 0.9% saline with 5% dextrose at standard maintenance rate
Study NCT00621348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypotonic fluid
Description: Reduced volume (two thirds of standard maintenance rate) of N/5 saline in 5% dextrose
Study NCT00621348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypotonic fluid
Description: N/5 saline in 5% dextrose at standard maintenance rate
Study NCT03402464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib combined dihydroaremisinin
Description: Icotinib should be taken by the patients continuously until disease progressed or intolerable toxicity. On day 1-3, oral dihydroaremisinin was given at 20mg per day, the dose of dihydroaremisinin is increased to 40mg daily on day 4 to 6, and 80mg twice daily until disease progressed or intolerable toxicity.
Study NCT03181646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citicoline
Description: intravenous citicoline 15 mg per kg per dose BD will be given to babies until oral feeds are established
Study NCT03671850 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VT-EBV-N
Description: Epstein-barr virus human cytotoxic T lymphocytes (EBV-CTL)
Study NCT03671850 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Peripheral blood mononuclear cell, PBMC
Study NCT01977872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A worksite activity-diet intervention
Study NCT00675467 — intervention group
Intervention type: BEHAVIORAL
Intervention: Focus Group - Parent/Caregiver
Description: A 1 1/2 hour group session with other parents/caregivers.
Study NCT00675467 — intervention group
Intervention type: BEHAVIORAL
Intervention: Focus Group - Pediatric Patient
Description: A 1 1/2 hour group session with other pediatric patients.
Study NCT02878980 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo supervised 1-on-1 exercise sessions
Study NCT02878980 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02878980 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01275807 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: 10 sessions of acupuncture
Study NCT01275807 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: self care
Description: physical exercice, diet, self help groups, psychological support
Study NCT03073837 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Rhinovirus Challenge
Description: Challenge with HRV-16 virus
Study NCT02395432 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: orotracheal intubation
Study NCT00606905 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gamimune N or Gamunex 10%
Description: 500 mg/kg administered in the follicular phase of the menstrual cycle. With conception, infusions every four weeks until 18-20 weeks of gestation.
Study NCT00606905 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: equivalent volume of normal saline
Study NCT04726540 — intervention group
Intervention type: OTHER
Intervention: Patient Satisfaction
Description: Patients were then asked to grade their overdentures/dentures on a visual analog scale and written questionnaire to evaluate their overall satisfaction.
Study NCT02878980 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02348515 — intervention group
Intervention type: PROCEDURE
Intervention: Heart failure or coronary disease
Description: Small samples collected from the apex core in the heart. In addition, blood samples will be taken.
Study NCT02348515 — intervention group
Intervention type: PROCEDURE
Intervention: Heart transplant patients
Description: Heart samples collected including, excess myocardial biopsy samples. In addition, blood samples will be taken.
Study NCT02348515 — intervention group
Intervention type: PROCEDURE
Intervention: Orthotopic Heart Transplant Patients
Description: Myocardial tissue samples collected from the diseased heart. In addition, blood samples will be taken.
Study NCT02348515 — intervention group
Intervention type: PROCEDURE
Intervention: Heart Surgery Patients
Description: Heart samples will be collected from the left atrial appendages. In addition, blood samples will be taken.
Study NCT02348515 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw
Description: All subjects will have 20 ml of blood drawn for further analysis.
Study NCT01910675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCC
Description: 15 IU/kg Octaplex and 2 g Riastab. Additional fibrinogen if needed.
Study NCT01910675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FFP
Description: 4 units Octaplas. Additional fibrinogen if needed.
Study NCT02851173 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LLLT
Description: The treatment will consist of applying light of a specific wavelength (1064 nm) using a laser diode supplied by Cell Gen Therapeutics, LLC (CG-5000 laser, HD Laser Center, Dallas, TX, USA).
Study NCT02851173 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The treatment will consist of applying light of a specific wavelength (1064 nm) using a laser diode supplied by Cell Gen Therapeutics, LLC (CG-5000 laser, HD Laser Center, Dallas, TX, USA). However, the placebo group will receive approximately 1/12th of the cumulative energy density as the treatment group.
Study NCT02531646 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation - Each human subject will receive one standard of care x-ray and one Duel Energy exposure or one standard of care x-ray and one Digital Tomosynthesis exposure. Phantoms were imaged using linear tomography and digital tomography.
Study NCT04384081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906
Description: Solution for injection
Study NCT04384081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection
Study NCT05571566 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Book
Description: An educational book with information about appendicitis for patients, parents and caregivers
Study NCT00640224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosiglitazone
Description: 4 mg daily for 6 months
Study NCT00640224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: drospirenone/ethinyl estradiol
Description: 1 tab (3mg/30mcg) daily for 6 months
Study NCT02948036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile-device, plasticity-based adaptive cognitive treatment
Description: This study employs a mobile-device delivered treatment program. Participants will be asked to use the assigned treatment program for approximately 30 minutes per session, up to seven sessions per week, over 6 weeks (42 total sessions).
Study NCT03616808 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thromboelastometry-guided haemostatic treatment
Description: Administration of blood products and/or procoagulants is based on thromboelastometric assays.
Study NCT04132271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized diet
Description: Modified texture and volumen diet according to the OD specifications
Study NCT04132271 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Nutritional Recommendations according to the OD specifications
Study NCT01883076 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous cell-based delivery
Description: autologous cells (derived from self)
Study NCT05944484 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: low caloric diet, ultrasound cavitation,Kegel exercises
Description: * low caloric diet (800-1200) calories/day,). According to each patient, diet contained (carbohydrate protein, fats, minerals, vitamins). 50 to 55% of total calories are carbohydrates, 10 to 15% of total calories protein. Fat limited to less than about 28% of daily total calories .Women took 1200 calories in the first month, 1000 calories in the second month, and 800 calories in the third month. Every week, each woman allowed to change the types of food to avoid boarding.~* ultrasound cavitation emits low-frequency ultrasound 40 khz for 30 minutes on abdomen twice/ week with 3 days apart for 12 weeks.~kegel exercise: Each woman in the study took the same Kegel exercise program performed the Kegel exercise for 12 weeks (3 sessions per week)
Study NCT00718653 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lutein
Description: Lutein (12 mg/d)
Study NCT00718653 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lutein plus green tea extract
Description: lutein (12 mg/d) plus green tea extract (200 mg/d)
Study NCT01787721 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ankle manipulation
Study NCT01787721 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham manipulation
Study NCT01206088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Description: administration of nilotinib as 2nd line
Study NCT03081936 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral consumption of Nutricia Aptamil Stage 1 formula
Description: Daily oral consumption of Nutricia Aptamil Stage 1 formula
Study NCT03081936 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral consumption of a2® Platinum Stage 1 formula
Description: Daily oral consumption of a2® Platinum Stage 1 formula
Study NCT03081936 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral consumption of breast milk
Description: Daily oral consumption of breast milk
Study NCT03133741 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: GIP-A
Description: GIP-A (GIP receptor antagonist)
Study NCT03133741 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: GLP-1 receptor antagonist Exendin[9-39]
Description: Exendin\[9-39\]
Study NCT03133741 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline (9mg/mL)
Study NCT03133741 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: GIP-A + Exendin[9-39]
Description: GIP receptor antagonist + GLP-1 receptor antagonist
Study NCT00947193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Oral powder
Study NCT03364270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET/CT Imaging with [F-18] RGD-K5
Description: PET Imaging/scan with \[F-18\] RGD-K5, PET Imaging/scan with RGD-K5, PET Imaging/scan with K5
Study NCT00955201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Structured aerobic exercise (treadmill).
Study NCT00955201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Structured isokinetic strength exercise (dynameter).
Study NCT03611257 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: dRAST
Description: Infectious diseases specialists will do active antimicrobial stewardship according to dRAST results in addition to Gram staining results and current standard method.
Study NCT03611257 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Current standard method
Description: Infectious diseases specialists will do active antimicrobial stewardship according to Gram staining results, and current standard method without dRAST results.
Study NCT02824406 — intervention group
Intervention type: DRUG
Intervention: Acetazolamide
Description: Acetazolamide is administered to all participants to induce vasodilation, in order to assess the physiologic response on cerebral blood flow.
Study NCT02274909 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TRAINING PROGRAM
Description: Sixty healthy elderly women were randomly divided into 3 groups: Pilates group (PG), PNF group (PNFG) and Control group (CG). Pilates and PNF groups underwent one-month training program with Pilates and PNF methods, respectively. CG received no intervention along the one month.
Study NCT01786772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy and compression
Description: Cryotherapy and intermittent pneumatic compression will be applied to the knee joint using a recirculating compression unit and knee sleeve. This unit will recirculate water which is between 1-3° C. Circumferential intermittent pneumatic compression to the knee joint (5 to 50 mm Hg) will be applied in conjunction with cryotherapy. The duration of intervention will be 20 minutes.
Study NCT01786772 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: Cryotherapy will be applied to the knee joint using a recirculating compression unit and knee sleeve. This unit will recirculate water which is between 1-3° C. The duration of intervention will be 20 minutes.
Study NCT03031080 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermoplastic Hand Splint
Description: Thermoplastic Night splint created and moulded to the individual patients hand in-house using generic thermoplastic.
Study NCT02385643 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SmartPhone Support System
Study NCT03680326 — intervention group
Intervention type: DEVICE
Intervention: OCT
Description: only OCT
Study NCT02644109 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phytosterol
Description: Day 1: Anthropometry, laboratory test, dietary intake (24 hour recall and food frequency questionnaire) and presence of symptoms and side effects will be determined, a logbook will be provided to record product consumption, symptoms, medications and side effects. Then will be randomly assigned to one of the groups.~Days 7 \& 21: 24 hour recall, review of symptoms, side effects and adherence as registered in the logbook.~Days 15 \& 30: Anthropometry, vital signs, venous blood sample, review of symptoms, side effects and adherence to intervention as registered on logbook, dietary intake (24-hour recall), delivery of monetary compensation proportional to the study days will be given before being discharged.
Study NCT02644109 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Day 1: Anthropometry, laboratory test, dietary intake (24 hour recall and food frequency questionnaire) and presence of symptoms and side effects will be determined, a logbook will be provided to record product consumption, symptoms, medications and side effects. Then will be randomly assigned to one of the groups.~Days 7 \& 21: 24 hour recall, review of symptoms, side effects and adherence as registered in the logbook.~Days 15 \& 30: Anthropometry, vital signs, venous blood sample, review of symptoms, side effects and adherence to intervention as registered on logbook, dietary intake (24-hour recall), delivery of monetary compensation proportional to the study days will be given before being discharged.
Study NCT01191762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevelamer carbonate
Description: 2400 mg with each meal for 4 weeks
Study NCT01191762 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 3 tablets with each meal
Study NCT04456855 — intervention group
Intervention type: PROCEDURE
Intervention: Locoregional surgery
Description: Patients had pathologically confirmed operable stage IV breast infiltrating carcinoma at initial presentation, and had locoregional surgery for the breast cancer.
Study NCT00947687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUR003
Description: Twice-daily (BID) doses of PUR003 will be delivered via inhalation using a commercially available nebulizer for a total of 7 days
Study NCT04451772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Upadacitinib
Description: Film-coated tablet; Oral
Study NCT00947687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03173183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: genuine regional Rhizoma Atractylodis (Maozhu granule)
Description: Maozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd.~Luozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd.~Simulants (granule), 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Group Co., Ltd.
Study NCT03173183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: genuine regional Rhizoma Atractylodis (Maozhu granule)
Description: Maozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd.~Luozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd.~Simulants (granule), 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Group Co., Ltd.
Study NCT03173183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: genuine regional Rhizoma Atractylodis (Maozhu granule)
Description: Maozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd.~Luozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd.~Simulants (granule), 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Group Co., Ltd.
Study NCT05764707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Patients will received 1000mg of intravenous acetaminophen within 30 minutes of skin closure.
Study NCT05764707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will received 1000mg of normal saline within 30 minutes of skin closure.
Study NCT02796261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eflornithine
Description: Eflornithine 2.8 g/m2 administered orally every 8 hours on a 2 week on, 1 week off schedule
Study NCT02796261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Lomustine 90 mg/m2 administered orally once every 6 weeks
Study NCT02796261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lomustine
Description: Lomustine 110 mg/m2 administered orally once every 6 weeks
Study NCT04380272 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The ROC analysis
Description: The Brodsky clinical stage and ultrasonographic data of the participants will be matched, and the diagnostic value of the submental US in the classification of tonsil hypertrophy as non-obstructive and obstructive will be evaluated. A ROC analysis will be used to determine the optimal cut-off value.
Study NCT04155580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX660
Description: Capsule for oral administration
Study NCT04155580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: Tablet for oral administration
Study NCT03223519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comboprofen
Description: Triple combination of Ibuprofen, Magnesium and Vitamin C Powder for oral solution administered TID for 3 days
Study NCT03223519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powder for oral solution administered TID for 3 days
Study NCT03223519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Powder for oral solution administered TID for 3 days
Study NCT03223519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium
Description: Powder for oral solution administered TID for 3 days
Study NCT03223519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Powder for oral solution administered TID for 3 days